A researcher from Bodoland University reports on a study investigating the binding property of ivermectin on four critical drug targets, including 1) spike protein, 2) RNA-dependent RNA polymerase, 3) 3-chymotrypsin-, and 4) papain-like proteases of SARS-CoV-2, the virus behind the COVID-19 pandemic. After conducting preclinical “in silica” investigations, the researcher’s docking study evinces that ivermectin was superior to lopinavir, as a binding drug against SARS-COV-2. The researcher found that not only did twenty-one amino acid residues of RdRp interact with ivermectin (including Asp760) but also RNA-RdRp complex demonstrated that the catalytic active residues Ser759 and Asp760 of RdRp created robust interactions with RNA chain. The author suggests evidence that ivermectin inhibits SARS-COV-2 replication as the antiparasitic drug binding in the active site of RdPp clashes with RNA chain nucleotides. The author concludes that ivermectin possibly inhibits RdRp possibly a crucial feature combatting SARS-CoV-2 and perhaps a reason for the growing positive findings when used to treat COVID-19.
Bodoland University, a state university located in Debargaon, Kokrajhar, Bodoland, was established in 2009 and represents the first and only university in the Bodoland Territorial Area Districts (BTAD) region. The affiliation of all the 23 colleges of the region with the university is shifted to Gauhati University until Bodoland University attains 12B status under the UGC Act.
Bodoland Territorial Region is an autonomous region in lower Assam in Northeast India. Made up of four districts, it is administered by an elected body known as the Bodoland Territorial Council, which came into terms under a peace accord in 2003.
Ananta Swargiary, PhD, MSc, Assistant Professor, Bodoland University